In a decision issued by the Federal Circuit on October 24, 2018, the court affirmed a finding by the Patent Trial and Appeal Board (PTAB) that a multiple sclerosis (MS) treatment claimed in an application owned by FWP IP APS (FWP) was not supported by adequate written description under 35 U.S.C. § 112. While the
Stephanie Scruggs is an experienced intellectual property attorney primarily focused on complicated patent disputes. Stephanie defends and enforces the IP rights of both U.S. and foreign-based clients in a wide range of industries, including the chemical, biochemical, pharmaceutical, electrical and mechanical fields.
M.S., Chemical Engineering
Patent Registration Number: 54,432